Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

Standard Dose
EQ 300MG BASE;EQ 45MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is listed in Drugs@FDA under application 014860 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE Form and strength TABLET;ORAL - EQ 300MG BASE;EQ 45MG BASE Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1990-05-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is listed in Drugs@FDA under application 014860 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE Form and strength TABLET;ORAL - EQ 300MG BASE;EQ 45MG BASE Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1990-05-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE (CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE) | Drug Monograph | MedicHelpline